Impact of body surface area on survival in EGFR-mutant non-small cell lung cancer patients treated with gefitinib monotherapy: observational study of the Okayama Lung Cancer Study Group 0703

详细信息    查看全文

• 作者：Kenichiro Kudo ; Katsuyuki Hotta ; Eiki Ichihara…
• 关键词：Lung cancer ; Gefitinib ; Body surface area ; EGFR ; TKI
• 刊名：Cancer Chemotherapy and Pharmacology
• 出版年：2015
• 出版时间：August 2015
• 年：2015
• 卷：76
• 期：2
• 页码：251-256
• 全文大小：412 KB
• 参考文献：1.Lynch TJ, BellDW Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non small-cell lung cancer to gefitinib. N Engl J Med 350:2129-139PubMed View Article
  2.Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-500PubMed View Article
  3.Pao W, Miller V, Zakowski M et al (2004) EGF receptor gene mutations are common in lung cancers from “never smokers-and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101:13306-3311PubMed Central PubMed View Article
  4.Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-57PubMed View Article
  5.Mitsudomi T, Morita S, Yatabe Y, et al for West Japan Oncology Group (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11:121-28
  6.Maemondo M, Inoue A, Kobayashi K et al; for North-East Japan Study Group (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380-388
  7.Fukuoka M, Yano S, Giaccone G et al (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 21:2237-246PubMed View Article
  8.Kris MG, Natale RB, Herbst RS et al (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290:2149-158PubMed View Article
  9.Ichihara E, Hotta K, Hisamoto A et al (2012) Impact of body surface area on efficacy of gefitinib in patients with non-small cell lung cancer harboring activating epidermal growth factor receptor mutation. J Clin Oncol 30(suppl; abstr 2607)
  10.DuBois D, DuBois EF (1916) A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 17:863-71View Article
  11.Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-47PubMed View Article
  12.Ichihara E, Hotta K, Takigawa N et al (2013) Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations. Lung Cancer 81:435-39PubMed View Article
  13.Mitsudomi T, Morita S, Yatabe Y et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11:121-28PubMed View Article
  14.Igawa S, Kasajima M, Ishihara M et al (2014) Evaluation of gefitinib efficacy according to body surface area in patients with non-small cell lung cancer harboring an EGFR mutation. Cancer Chemother Pharmacol 74:939-46PubMed View Article
  15.Larson RA, Druker BJ, Guilhot F et al (2008) Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111:4022-028PubMed View Article
  16.Kawaguchi T, Hamada A, Hirayama C et al (2009) Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemia. Int J Hematol 89:642-48PubMed View Article
  17.Nakamura Y, Sano K, Soda H et al (2010) Pharmacokinetics of gefitinib predicts antitumor activity for advanced non-small cell lung cancer. J Thorac Oncol 5:1404-409PubMed View Article
  18.Sacco JJ, Botten J, Macbeth F, Bagust A, Clark P (2010) The average body surface area of adult cancer patients in the UK: a multicentre retrospective study. PLoS One 5:e8933PubMed Central PubMed View Article
  
• 作者单位：Kenichiro Kudo (1)
  Katsuyuki Hotta (1) (2)
  Eiki Ichihara (1)
  Hiroshige Yoshioka (3)
  Kei Kunimasa (3)
  Kazuya Tsubouchi (3)
  Masahiro Iwasaku (3)
  Yuka Kato (1)
  Isao Oze (4)
  Nagio Takigawa (5)
  Mitsune Tanimoto (2)
  Katsuyuki Kiura (1)
  
  1. Department of Respiratory Medicine, Okayama University Hospital, 2-5-1, Shikata-cho, Kitaku, Okayama, 700-8558, Japan
  2. Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan
  3. Department of Respiratory Medicine, Kurashiki Central Hospital, Okayama, Japan
  4. Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Aichi, Japan
  5. Department of General Internal Medicine 4, Kawasaki Hospital, Kawasaki Medical School, Okayama, Japan
  
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Biomedicine
  Cancer Research
  Pharmacology and Toxicology
  Oncology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-0843

文摘

Background The approved dose of gefitinib is fixed, without adjustment for physical size. We demonstrated previously that its efficacy was affected by body surface area (BSA) in patients with EGFR-mutant non-small cell lung cancer (NSCLC). To validate these observations, we assessed the association between BSA and the efficacy of gefitinib using a different patient cohort. Methods Prospective cohort data from 115 NSCLC patients with EGFR-mutant tumours, who received gefitinib monotherapy between 2007 and 2012, were analysed. Results Gefitinib was less effective in individuals with a high BSA (?.5?m2) in EGFR-mutant NSCLC compared with those with a low BSA (<1.5?m2). The median progression-free survival (PFS) in the high- and low-BSA groups was 4.2 and 8.5?months, respectively, although there was no difference in survival among the whole NSCLC cohort. Multivariate analysis also showed a significant effect of BSA on PFS (hazard ratio 1.72; 95?% confidence interval 1.08-.74; p?=?0.021). Sensitivity analysis revealed that the use of the BSA cut-off level around 1.50?m2 was robust for detecting subpopulations that would benefit less from gefitinib monotherapy. Conclusion We found in the prospective cohort data that BSA could affect the efficacy of gefitinib monotherapy in patients with EGFR-mutant NSCLC, suggesting that BSA-based dose setting of gefitinib monotherapy might be further investigated, despite the fact that no molecular-targeted agent described to date undergoes dose adjustment according to BSA.